CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $8.95B, above the global median of $1.16B
- PositionGross margin is 99.4%, higher than 95% of its Biotechnology peers (median 75.8%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.95BUSDvs all stocks (USD)
Revenue (TTM)
165.79MUSDvs all stocks (USD)
Beta
0.1350xvs all stocks
52-Week Change
228.41%vs all stocks
Market Capitalization
8.95BUSDvs all stocks (USD)
Enterprise Value
9.82BUSDvs all stocks (USD)
Forward P/E
-66.63xvs Biotechnology peers
Price to Sales (TTM)
53.95xvs Biotechnology peers
Enterprise to Revenue
59.21xvs Biotechnology peers
Enterprise to EBITDA
-41.72xvs Biotechnology peers
Gross Margin
99.42%vs Biotechnology peers
Operating Margin
-120.41%vs Biotechnology peers
Return on Assets (TTM)
-30.54%vs Biotechnology peers
Revenue (TTM)
165.79MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.1650USDUpdated Sep 27, 2026Quarterly Revenue Growth
93.90%vs Biotechnology peers
Gross Profit (TTM)
164.70MUSDvs all stocks (USD)
EBITDA (TTM)
-235.30MUSDvs all stocks (USD)
Net Income (TTM)
-992.36MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
93.91%vs Biotechnology peers
Operating Cash Flow (TTM)
-281.14MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-186.56MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
895.00KUSDFY2025 · Dec 31, 2025Revenue
113.29MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
753.00KUSDFY2025 · Dec 31, 2025Gross Profit
112.53MUSDFY2025 · Dec 31, 2025Operating Income
-256.03MUSDvs all stocks (USD)
Pre-tax Income
-351.61MUSDFY2025 · Dec 31, 2025Income Tax Expense
-135.00KUSDFY2025 · Dec 31, 2025Net Income
-351.47MUSDFY2025 · Dec 31, 2025EBIT
-239.08MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-282.76MUSDFY2025 · Dec 31, 2025Research & Development
218.56MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
150.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.69MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
112.53MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.3800USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.3800USDFY2025 · Dec 31, 2025Basic Shares Outstanding
919.86MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
919.86MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-351.47MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
74.00KUSDFY2025 · Dec 31, 2025Operating Cash Flow
-261.22MUSDFY2025 · Dec 31, 2025Free Cash Flow
-265.06MUSDDerived from operating cash flow minus capital expenditure. This filing charges 15.53M of depreciation against 3.85M of capital expenditure, and its own free-cash-flow line reads -309.19M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
89.43MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Interest Paid
71.32MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-351.47MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
15.53MUSDFY2025 · Dec 31, 2025Stock-based Compensation
36.81MUSDFY2025 · Dec 31, 2025Other Non-cash Items
90.58MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-40.21MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-190.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-12.26MUSDFY2025 · Dec 31, 2025Capital Expenditures
-3.85MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-406.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-241.37MUSDFY2025 · Dec 31, 2025Sale of Investments
95.82MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-149.40MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-28.00KUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
2.88MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.13MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
402.29MUSDFY2025 · Dec 31, 2025Shares Outstanding
1.05BSharesUpdated Sep 27, 2026Float Shares
406.64MSharesUpdated Sep 27, 2026Shares Short
125.41MSharesUpdated Sep 27, 2026Short Ratio
15.07daysvs all stocks
Short % of Shares Outstanding
31.28%vs all stocks
% Held by Insiders
62.17%vs all stocks
% Held by Institutions
19.80%vs all stocks
Total Cash (MRQ)
357.37MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.3370USDUpdated Sep 27, 2026Total Debt (MRQ)
1.23BUSDvs all stocks (USD)
Current Ratio (MRQ)
5.72xvs Biotechnology peers
Book Value per Share (MRQ)
-0.9940USDUpdated Sep 27, 2026Total Assets
501.90MUSDvs all stocks (USD)
Total Current Assets
314.88MUSDFY2025 · Dec 31, 2025Total Liabilities
1.00BUSDFY2025 · Dec 31, 2025Total Non-current Assets
187.02MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
939.72MUSDFY2025 · Dec 31, 2025Total Current Liabilities
61.75MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
88.33MUSDFY2025 · Dec 31, 2025Other Short-term Investments
154.48MUSDFY2025 · Dec 31, 2025Accounts Receivable
42.57MUSDFY2025 · Dec 31, 2025Inventory
910.00KUSDFY2025 · Dec 31, 2025Accounts Payable
6.98MUSDFY2025 · Dec 31, 2025Short-term Debt
7.54MUSDFY2025 · Dec 31, 2025Other Current Liabilities
3.07MUSDFY2025 · Dec 31, 2025Long-term Debt
510.54MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
325.04MUSDFY2025 · Dec 31, 2025Common Stock (Book)
101.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-3.73BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-499.57MUSDvs all stocks (USD)
52-Week Low
1.95USDUpdated Sep 27, 202652-Week High
12.43USDUpdated Sep 27, 202652-Week Change
228.41%vs all stocks
Beta
0.1350xvs all stocks
50-Day MA
7.81USDUpdated Sep 27, 2026200-Day MA
7.00USDUpdated Sep 27, 2026Avg 10-Day Volume
12.70MSharesUpdated Sep 27, 2026Avg 30-Day Volume
9.62MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-0.9500USDUpdated Sep 27, 2026Other Income / Expense
14.26MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 99.4%, higher than 95% of its Biotechnology peers (median 75.8%)Significant
Gross margin: 0.99Industry median: 0.76Industry P95: 0.98Peers compared: 184
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.66
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $8.95B, above the global median of $1.16BNotable
Market cap (USD): 8,945,018,144Global Median: 1,162,498,137.938
Companies that share the same coordination system — how they create, deliver, or capture value.
Cytokinetics, Incorporated
Tier 1ProductionApproval-Gated PipelineRuleRisk
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. A Shares
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Crinetics Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
TG Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Glaukos Corporation
Tier 1ProductionApproval-Gated PipelineRule
Protagonist Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kymera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Arrowhead Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aurobindo Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Fastly Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Twist Bioscience Corporation
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Via Transportation, Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC